Paroxysmal Supraventricular Tachycardia Market Size was valued at USD 0.28 Billion in 2023. The Paroxysmal Supraventricular Tachycardia industry is projected to grow from USD 0.30 Billion in 2024 to USD 0.52 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.30% during the forecast period (2024 - 2032). Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate that is caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heart beating. People suffering from this disorder experience sudden and unexpected occurrence of rapid heart rate that start and stop without warning. A normal heart beats between 60 to 100 beats per minute, but the heart rate of a person suffering from paroxysmal supraventricular tachycardia during an episode may exceed 150–200 beats per minute.
The prevalence of Paroxysmal Supraventricular Tachycardia (PSVT) is unknown but is projected to be around several cases per thousand persons. But, a recent study conducted by Milestone Pharmaceuticals suggested that about 1.7 million patients in the U.S. were suffering from paroxysmal supraventricular tachycardia since the last five years.
The most common types of arrhythmias include atrial fibrillation, atrial flutter, sick sinus syndrome, sinus tachycardia, supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, and premature ventricular contractions. Moreover, some arrhythmias may lead to more serious medical problems such as sudden stroke or cardiac arrest.
Intended Audience
Figure 1: Paroxysmal Supraventricular Tachycardia (PSVT) Market Share, by Region
The Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented on the basis of type, diagnosis, treatment, and end-user.
On the basis of type, the Paroxysmal Supraventricular Tachycardia (PSVT) market is segmented into AV Nodal Re-Entrant Tachycardia (AVNRT), AV Reciprocating Tachycardia (AVRT), Paroxysmal Atrial Tachycardia (PAT), and Wolff-Parkinson-White Syndrome (WPW).
On the basis of diagnosis, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into Electrophysiology Study (EPS), stress test, cardiac catheterization, coronary angiography, Electrocardiogram (ECG), echocardiogram, Holter monitor, event monitor, implantable monitor, lab tests, and others. Lab tests are further classified into blood test, urine test, and others.
On the basis of treatment, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into physical maneuvers, medications, catheter ablation, pacemaker, and cardioversion. Medication can be segmented into calcium channel blockers, beta blockers, antiarrhythmic medication, and others. Calcium channel blockers are further divided into diltiazem, verapamil, and others. The antiarrhythmic medication is divided into sotalol, amiodarone, amiodarone, flecainide, propafenone, and adenosine.
On the basis of end-user, the Paroxysmal Supraventricular Tachycardia (PSVT) market is classified into hospitals and clinics, diagnostic centers, medical research centers, and others.
Research Methodology
Sources: Annual reports, Press release, White paper, and Company presentation
The Paroxysmal Supraventricular Tachycardia (PSVT) market consists of four major regions, namely, the Americas, Europe, Asia Pacific, and the Middle East and Africa.
The Americas dominates the market owing to the key players domiciled in these regions coupled with the increasing incidences of stroke, raising awareness among people, and increasing healthcare expenditure. Coronary artery diseases, heart valve disorders, and heart failures are some of the common causes of heart diseases occurring in adults in North America. Thus, the increasing occurrences of heart failure support the growth of paroxysmal supraventricular tachycardia in this region.
Asia Pacific is estimated to be the most lucrative market for PSVT due to the increasing occurrence of multiple heart disorders in Asia Pacific such as China and others. The growth in the Asian market is fueled by the expanding healthcare infrastructure and presence of untapped market opportunities in this region. This region is considered as an emerging market owing to the increasing number of manufacturers coupled with the increasing market penetration.
The growing prevalence of coronary heart diseases along with the increasing medical tourism that requires surgical procedures are favoring the growth of the market in the Middle East and Africa. In addition, the development of drug delivery technologies, a combination of modern diagnostic techniques, and increasing awareness of various types of heart disorders are similarly supporting the growth of paroxysmal supraventricular tachycardia market.
Some of the key players in the Paroxysmal Supraventricular Tachycardia (PSVT) market are:
| Report Attribute/Metric | Details |
| Market Size | USD 0.52 Billion |
| CAGR | 6.30% |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2021 |
| Forecast Units | Value (USD Billion) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Type, Diagnosis, Treatment, and End-user |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | GlaxoSmithKline PLC (U.K.), Novartis AG (Switzerland), Pfizer, Inc. (U.S.), AstraZeneca PLC (U.K.), Teva pharmaceutical industries (Israel), Sanofi SA (France), Medtronic, Inc. (U.S.), Glenmark Pharmaceuticals (U.S.), St. Jude Medical, Inc. (U.S.), BIOTRONIK SE & Co. KG (U.S.), GE Healthcare (U.S.), Boston Scientific Corporation (U.S.), Abbott Laboratories Inc. (U.S.), (Alcon) Novartis (U.S.), Siemens AG (Germany), Koninklijke Philips N.V. (U.S.), and others |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | · Increasing demand for diagnostic outpatient surgeries · Increasing healthcare services · Availability of low cost of labor · Increasing number of hospitals, and better access to technology |
Paroxysmal Supraventricular Tachycardia Market Highlights:
Frequently Asked Questions (FAQ) :
Supraventricular tachycardia is a condition where there is a rapid increase in the heart rate caused by electrical impulses originating above the heart. Paroxysmal supraventricular tachycardia, also known as PSVT, is a condition wherein the patient shows an irregularity in heartbeats.
Paroxysmal Supraventricular Tachycardia Market is expected to exhibit a strong 6.30% CAGR over the forecast period from 2024 to 2032.
Growing prevalence of cardiovascular diseases is the major driver for the Paroxysmal Supraventricular Tachycardia Market.
The Americas dominate the global Paroxysmal Supraventricular Tachycardia Market.
Leading players in the Paroxysmal Supraventricular Tachycardia Market include GSK, Novartis, and Pfizer, among others.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
